Every 8-K that Amneal Pharmaceuticals Inc (AMRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMRX filings page.
Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, purchasing 100% of Kashiv’s membership interests through its wholly owned subsidiary Amneal Pharmaceuticals LLC. The consideration at closing included $375,000,000 in cash, subject to purchase price adjustments, and the issuance of 28,942,098 shares of Class A common stock as stock consideration to the sellers.
Under the purchase agreement, the sellers may receive up to an additional $350,000,000 in contingent payments tied to specified U.S. regulatory milestones for up to six Kashiv product candidates, plus potential contingent royalty payments over 12 years equal to 25% of certain annual gross profits above defined hurdles. To help fund the transaction, Amneal LLC entered into an amendment to its term loan credit agreement, under which Bank of America, N.A. provided a $350,000,000 incremental term loan.
Amneal amended its Stockholders Agreement to ensure the new stock consideration is counted in Amneal Group ownership calculations and relied on a private-offering exemption to issue the shares to accredited investors. The company plans to file an S-3 registration statement to permit public resale of the stock consideration and will later provide Kashiv’s financial statements and pro forma financial information.
Amneal Pharmaceuticals, Inc., through subsidiary Amneal Pharmaceuticals LLC, entered into Amendment No. 3 to its Term Loan Credit Agreement, converting on a cashless basis existing term loans into new term loans with an aggregate principal amount of $2.039 billion and incurring an additional $45.2 million term loan used to prepay at par remaining existing loans.
The amendment reduces the interest rate margin on these Amendment No. 3 Term Loans by 50 basis points to 1.50% for base rate loans and 2.50% for loans based on the secured overnight financing rate, while keeping the stated maturity at August 1, 2032. It also permits a future repricing transaction without a prepayment premium if it occurs after February 3, 2027. The company estimates annualized cash interest expense savings of approximately $12 million compared with the prior credit agreement, based on amounts outstanding immediately before the amendment.
Amneal Pharmaceuticals, Inc. reported that stockholders at a July 31, 2026 special meeting approved the Transaction Proposal to enter into the Membership Interest Purchase Agreement and acquire 100% of the issued and outstanding membership interests of Kashiv BioSciences, LLC. Disinterested stockholders cast 138,265,079 votes for, 655,759 against and 67,147 abstaining, satisfying the required approval condition.
Stockholders also approved the Stock Issuance Proposal to issue 28,942,108 shares of Class A common stock to the Kashiv sellers for Nasdaq Listing Rule 5635(a)(2) compliance, with 286,714,072 votes for, 1,791,016 against and 62,071 abstentions. Of 319,331,346 shares outstanding on the June 25, 2026 record date, 288,567,159 were represented, constituting a quorum. Closing of the Kashiv transaction is expected in the second half of 2026, assuming all remaining conditions and required regulatory approvals are satisfied.
Amneal Pharmaceuticals reported Q2 2026 net revenue of $796 million, up 10% from $725 million a year earlier. Net income attributable to Amneal was $58 million, with diluted EPS of $0.18. Adjusted EBITDA was $206 million and adjusted diluted EPS $0.30, both higher than Q2 2025.
Specialty net revenue grew 17%, Affordable Medicines rose 13%, while AvKARE declined 4%. For the first half of 2026, net cash (used in) provided by operating activities was $(47,987) thousand versus $91,227 thousand provided in the prior-year period.
The company repriced its $2.084 billion Term Loan B, cutting the rate by 50 bps to SOFR plus 250 bps, expected to save about $12 million in annual cash interest, and plans an additional $350 million Term Loan B to help fund the pending Kashiv BioSciences acquisition. 2026 guidance was raised: net revenue to $3.10–$3.20 billion, adjusted EBITDA to $750–$780 million, and adjusted diluted EPS to $0.96–$1.06. Net debt was $2.66 billion with non-GAAP net leverage of 3.6x for the last twelve months ended June 30, 2026.
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026. Stockholders elected all 11 director nominees, including Deb Autor, Chintu Patel, Chirag Patel and Gautam Patel, to serve until the 2027 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the selection of Ernst & Young LLP as Amneal’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Amneal Pharmaceuticals reported strong first quarter 2026 results. Net revenue was $722.5 million, up 4% from $695.4 million a year earlier, driven by 23% Specialty growth and 2% Affordable Medicines growth, partly offset by a 4% AvKARE decline.
Net income attributable to Amneal rose to $62.3 million from $12.2 million, while adjusted EBITDA increased 19% to $202.0 million. Diluted EPS was $0.19 versus $0.04, and adjusted diluted EPS was $0.27 versus $0.21, reflecting higher revenue and improved gross margins.
The company affirmed its increased 2026 outlook, guiding to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $740–$770 million, adjusted diluted EPS of $0.95–$1.05, operating cash flow of $350–$400 million, and about $110 million in capital expenditures.
Amneal Pharmaceuticals agreed to acquire 100% of Kashiv BioSciences, paying $375 million in cash and issuing 28,942,108 Class A shares at closing, plus up to $350 million in regulatory milestone payments and potential royalties based on future gross profits.
The deal, expected to close in the second half of 2026 subject to shareholder and regulatory approvals, is intended to create a scaled, fully integrated global biosimilars platform. An independent conflicts committee approved the transaction terms and will recommend that stockholders approve the stock issuance and Purchase Agreement.
Alongside the deal, Amneal reported strong preliminary Q1 2026 results, with net revenue of $723 million, net income of $78 million and adjusted EBITDA of $202 million, and raised 2026 guidance for adjusted EBITDA, adjusted diluted EPS and operating cash flow.
Amneal Pharmaceuticals reported strong fourth quarter and full-year 2025 results, returning solidly to profitability and increasing cash generation. Q4 2025 net revenue rose 11% to $814 million, with GAAP net income of $35 million and diluted EPS of $0.11, while adjusted EBITDA reached $175 million and adjusted diluted EPS was $0.21.
For 2025, net revenue grew to $3.02 billion from $2.79 billion, and net income attributable to Amneal improved to $72 million from a $117 million loss, driven by higher revenue, better gross profit and lower expenses. Adjusted EBITDA increased 10% to $688 million and adjusted diluted EPS rose to $0.83. Specialty revenue grew 19%, Affordable Medicines 4%, and AvKARE 12%.
For 2026, Amneal guides to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $720–$760 million, adjusted diluted EPS of $0.93–$1.03, and operating cash flow of $325–$375 million. Net debt was $2.41 billion at December 31, 2025, implying net leverage of 3.5x, down from 3.9x a year earlier.
Amneal Pharmaceuticals, Inc. amended its term loan credit agreement through a repricing transaction. Existing term loans held by consenting lenders were converted on a cashless basis into new term loans totaling $1,960,076,527.50, and the company added a new term loan of $134,673,472.50 to refinance remaining old loans at par.
The amendment lowers the interest rate margin on the new term loans by 50 basis points to 2.00% for base rate loans and 3.00% for loans based on the secured overnight financing rate, while keeping the August 1, 2032 maturity date unchanged. Amneal estimates approximately $11 million in annualized cash interest savings from this repricing, improving its ongoing financing costs.
Amneal Pharmaceuticals is moving ahead with a nationwide agreement to settle a substantial majority of opioids-related claims brought by states and local subdivisions. The settlement becomes effective on January 29, 2026.
Under the agreement, Amneal will pay participating states and subdivisions $88.5 million in cash and provide up to $177.4 million in naloxone nasal spray, valued at $125 per twin pack, to help treat opioid overdoses. Instead of product, settling parties may elect to receive 25% of the naloxone value, up to $44.4 million in additional cash during the final four years of the ten‑year payment term, which would bring the total cash commitment up to $132.9 million.
Amneal Pharmaceuticals plans to tell investors it expects to meet or exceed its previously issued 2025 full-year financial guidance. The company continues to target net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $675 million to $685 million, adjusted diluted EPS of $0.75 to $0.80, operating cash flow of $300 million to $330 million, and capital expenditures of about $100 million net of a $20 million alliance contribution.
Amneal also estimates its net leverage as of December 31, 2025 to be about 3.6x, improved from 3.9x a year earlier. The outlook relies on management’s assumptions about prescription trends, pricing, product launches, restructuring impacts and strategy execution, and uses several non-GAAP measures such as adjusted EBITDA, adjusted diluted EPS and net leverage, which exclude items like acquisition and restructuring costs, legal charges and certain non-cash expenses.
Amneal Pharmaceuticals (AMRX) furnished an 8‑K announcing it issued a press release for its third quarter ended September 30, 2025. The information was provided under Item 2.02 and Item 7.01 and is being treated as furnished, not filed.
Amneal will host a conference call and live webcast at 8:30 a.m. Eastern Time on October 30, 2025. Access the webcast via the Investor Relations site at https://investors.amneal.com or join by phone at (833) 470‑1428 (U.S.) with access code 272787. A replay will be posted after the call, with international dial-in options available at the provided NetRoadshow link.
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K announcing a two-part debt refinancing initiative. Its operating subsidiary is marketing $1.8 billion of new seven-year term loan B debt and has launched a private offering of $750 million senior secured notes due 2032. Net proceeds are earmarked to (i) refinance the company’s existing term B loans in full, (ii) repay a portion of borrowings under the ABL facility, and (iii) cover related fees and expenses.
The notes will be issued under Rule 144A/Reg S and will not be registered with the SEC. Completion, size and terms of both transactions remain subject to market conditions; the notes offering is not contingent on closing of the new term loan facility. No financial results or forward guidance were provided.
Key takeaways for investors:
- Potentially extends weighted-average debt maturity to 2032.
- Transaction could restructure up to $2.55 billion of the capital stack.
- Execution risk exists because neither transaction is assured.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) filed an 8-K dated 21-Jul-2025 disclosing two principal items:
- Item 2.02 – Preliminary Q2 2025 results: The company issued a press release (Ex. 99.1) with unaudited second-quarter figures. Numerical details are not included in the filing; the release is incorporated by reference but treated as “furnished,” not “filed,” under the Exchange Act.
- Item 5.02 – Board change: Ownership of Class A shares held by Amneal Group investors fell below a majority threshold, reducing their Board designee rights from six to five under the Stockholders Agreement. Consequently, Amneal Group designee Emily Peterson Alva resigned from the Board and Audit Committee effective 16-Jul-2025. The company states the resignation involved no disagreement with management, the Board, or company policies.
No other material transactions, financial statements, or guidance updates are provided in this report. The filing contains customary Regulation FD and exhibit listings.